logo

Lipocine Inc (LPCN)



Trade LPCN now with
  Date
  Headline
5/9/2022 8:16:03 AM Lipocine Q1 Net Loss $3.5 Mln Or $0.04/shr Vs Net Loss Of $3.4 Mln Or $0.04/shr Prior Year
4/11/2022 8:00:00 AM LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS (Press Release)
3/29/2022 7:13:39 AM Lipocine: FDA Approves TLANDO As Oral Testosterone Replacement Therapy In Adult Males For Hypogonadism
3/1/2022 8:10:44 AM Lipocine Reports Regulatory Guidance On LPCN 1144 In Non-cirrhotic NASH
2/3/2022 8:22:58 AM Lipocine Says Its Partner Received FDA Acceptance Of NDA Resubmission For Tlando
11/10/2021 8:11:31 AM Lipocine Q3 Net Loss $3.1 Mln Or $0.03/shr Vs. Net Loss Of $4.3 Mln, Or $0.07/shr Prior Year
11/4/2021 8:32:30 AM Lipocine Gets FDA Fast-Track Designation For LPCN 1144 In Non-Cirrhotic NASH
11/1/2021 8:12:04 AM Lipocine Announces Presentations At American Association For Study Of Liver Diseases (AASLD) Liver Meeting 2021
9/28/2021 8:17:55 AM Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO, Oral Testosterone Product
8/25/2021 6:34:56 AM Lipocine's LPCN 1144 Meets NASH Resolution Regulatory Endpoint In Phase 2 LiFT Study
8/5/2021 8:15:05 AM Lipocine Q2 Net Loss Of $6.8 Mln Or $0.08/shr Vs. Loss Of $6.4 Mln Or $0.13/shr Prior Year
7/14/2021 4:08:55 PM Lipocine Announces Settlement With Clarus Therapeutics
5/26/2021 8:47:48 AM Lipocine Says Disappointed In Court' Decision Of Granting Clarus Therapeutics' Motion For Summary Judgment